产品管线

Overall pipeline diagram

Project Code Target Indication Preclinical IND Phase I Phase II/III BLA

SDT-T001 - Postoperative recurrence prevention of liver cancer 2025.04-2028.12 Expected 2029 Q2

SDT-T002 - advanced cancer 2025.09-2029Q4 Expected 2030 Q2

SDT-M001 - Postoperative recurrence prevention of lung cancer 2024.12-2026.10 2026.12-2028.12 Expected 2029 Q2

SDT-M002 - colorectal cancer Expected to receive IND approval in Q1 2027 Seamless transition from Phase Ib to Phase II Expected 2031

SDT-M003 - Combination therapy of PD-L1 antibody for advanced solid tumors 2027 Q4 Expected to receive IND approval in Q1/Q2 2028 Expected 2032-2033

SDT-UT001 CD19/BCMA Autoimmune diseases 2029 Q3 It is expected to enter the IND stage in Q4 2029

SDT-UT002 GUCY2C/CDH6/
Cd276 solid tumor 2028 Q4 It is expected to enter the IND stage in 2029

Tcm Immune Cell Therapy SeriesCytocraft has fully mastered the core technology and does not rely on gene editing. It uses central memory T cells (Tcm) as the main component of autologous cell preparations, possessing dual functions of treating tumors and preventing recurrence.

SDT-T001 The indication for SDT-T001 injection is to prevent recurrence after liver cancer surgery. SDT-T002 The indication for SDT-T002 injection is for patients with advanced hepatocellular carcinoma who have failed standard treatment.

CARPI Immune Cell Therapy SeriesThis series is independently developed by Cytocraft and is based on the patient's peripheral blood to construct a non-gene-modified autologous polyclonal tumor-specific T cell cluster, which has anti-tumor activity and potential for preventing recurrence after surgery.

SDT-M001 This product is mainly used for postoperative recurrence prevention of non-small cell lung cancer. After reinfusion, specific T lymphocytes with natural anti-tumor ability can be supplemented to the patient's body, improving the body's immunity and enhancing the monitoring and killing effect of T cells on tumor cells. SDT-M002 This product is intended for patients with colorectal cancer after radical surgery and is currently in the IIT research stage. SDT-M003 This product is mainly used in combination with PD-L1 to treat various advanced malignant solid tumors. After reinfusion, the target enhances T cell immune response and improves immune microenvironment related inhibitory factors.

UCAR-T Immune Cell Therapy SeriesThe raw materials are collected from healthy PBMCs, and a unique non gene editing technique, namely protein expression internalization, is used to efficiently downregulate TCR/HLA expression, theoretically reducing the risk of off target genes and minimizing damage to T cells.

SDT-UT001 SDT-UT001 is a universal CAR-T (CD19/BCMA UCAR-T) product developed based on CD19/BCMA dual targets. SDT-UT002 SDT-UT002 is a universal CAR-T product developed based on GUCY2C/CDH6/CD276 multi-target technology.

What do you want to inquire about?